In this supplement to Current Psychiatry, Greg Mattingly, MD and Manish K. Jha, MBBS review dilemmas and treatment options for patients with tardive dyskinesia.
This activity is supported by an independent educational grant from Neurocrine …
Sponsor
This activity is supported by an independent educational grant from Neurocrine …
In this supplement to Current Psychiatry, Greg Mattingly, MD and Manish K. Jha, MBBS review dilemmas and treatment options for patients with tardive dyskinesia.
In this supplement to Current Psychiatry, Greg Mattingly, MD and Manish K. Jha, MBBS review dilemmas and treatment options for patients with tardive dyskinesia.
This article traces the evolution of estrogen in contraception, with a special focus on the concept of native estrogen with specific actions in tissues, or NEST. Research surrounding estetrols (E4), receptor binding, and target interactions demonstrate that E4 has high selectivity for the estrogen receptors. Clinical trial data are presented that support the view that E4 — a high NEST activity estrogen — is a safe and effective estrogen for use in combined oral contraceptives. This premise was borne out with the approval of an estetrol/drosperinone combined oral contraceptive by the US Food and Drug Administration in April 2021.
CME CREDITS: .25 CREDIT To receive CME credit, please read the articles and go to www.omniaeducation.com/estrogen to access the posttest and evaluation.
Authors:
Patricia Geraghty, MSN, FNP-BC, WHNP Hugh S. Taylor, MD
Sponsor
This activity is supported by an independent educational grant from Mayne Pharm…
This activity is supported by an independent educational grant from Mayne Pharm…
Sponsor
This activity is supported by an independent educational grant from Mayne Pharm…
Free CME Credit
This article traces the evolution of estrogen in contraception, with a special focus on the concept of native estrogen with specific actions in tissues, or NEST. Research surrounding estetrols (E4), receptor binding, and target interactions demonstrate that E4 has high selectivity for the estrogen receptors. Clinical trial data are presented that support the view that E4 — a high NEST activity estrogen — is a safe and effective estrogen for use in combined oral contraceptives. This premise was borne out with the approval of an estetrol/drosperinone combined oral contraceptive by the US Food and Drug Administration in April 2021.
CME CREDITS: .25 CREDIT To receive CME credit, please read the articles and go to www.omniaeducation.com/estrogen to access the posttest and evaluation.
Authors:
Patricia Geraghty, MSN, FNP-BC, WHNP Hugh S. Taylor, MD
Free CME Credit
This article traces the evolution of estrogen in contraception, with a special focus on the concept of native estrogen with specific actions in tissues, or NEST. Research surrounding estetrols (E4), receptor binding, and target interactions demonstrate that E4 has high selectivity for the estrogen receptors. Clinical trial data are presented that support the view that E4 — a high NEST activity estrogen — is a safe and effective estrogen for use in combined oral contraceptives. This premise was borne out with the approval of an estetrol/drosperinone combined oral contraceptive by the US Food and Drug Administration in April 2021.
CME CREDITS: .25 CREDIT To receive CME credit, please read the articles and go to www.omniaeducation.com/estrogen to access the posttest and evaluation.
Authors:
Patricia Geraghty, MSN, FNP-BC, WHNP Hugh S. Taylor, MD
Despite the availability of a variety of effective antidepressants, the burden of inadequately treated major depressive disorder (MDD) in the United States remains deeply troubling. Primary care providers (PCPs) have a key role to play in alleviating the burden of inadequately treated MDD. In this supplement, we discuss practical strategies PCPs can use to ensure that their patients with MDD receive optimal treatment, focusing on patient-centered approaches that work in the real world.
After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at www.cmesurvey.site/MDDJFP
Sponsor
This supplement is jointly provided by Medical Education Resources and CMEology…
This supplement is jointly provided by Medical Education Resources and CMEology…
Sponsor
This supplement is jointly provided by Medical Education Resources and CMEology…
Despite the availability of a variety of effective antidepressants, the burden of inadequately treated major depressive disorder (MDD) in the United States remains deeply troubling. Primary care providers (PCPs) have a key role to play in alleviating the burden of inadequately treated MDD. In this supplement, we discuss practical strategies PCPs can use to ensure that their patients with MDD receive optimal treatment, focusing on patient-centered approaches that work in the real world.
After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at www.cmesurvey.site/MDDJFP
Despite the availability of a variety of effective antidepressants, the burden of inadequately treated major depressive disorder (MDD) in the United States remains deeply troubling. Primary care providers (PCPs) have a key role to play in alleviating the burden of inadequately treated MDD. In this supplement, we discuss practical strategies PCPs can use to ensure that their patients with MDD receive optimal treatment, focusing on patient-centered approaches that work in the real world.
After reviewing the learning objectives and reading the supplement, please complete the Activity Evaluation/Credit Request form online at www.cmesurvey.site/MDDJFP
Abdominal pain, bloating, diarrhea, and constipation are common complaints encountered in primary care clinics, and usually suggest problems affecting the lower half of the gastrointestinal (GI) tract. The most common diagnoses for patients with these symptoms, when chronic in nature, are irritable bowel syndrome (IBS) and chronic constipation, with an estimated pooled community prevalence of 11.2% and 14%, respectively. IBS and chronic constipation represent a substantial burden to patients and society in terms of daily symptoms, quality of life (QoL), work productivity, and health care costs. Indeed, patients experience chronic, disruptive symptoms for many years prior to seeking health care and typically report lengthy and complex treatment histories.
Supported by educational grants from Salix Pharmaceuticals and Takeda Pharmaceu…
Sponsor
Supported by educational grants from Salix Pharmaceuticals and Takeda Pharmaceu…
Abdominal pain, bloating, diarrhea, and constipation are common complaints encountered in primary care clinics, and usually suggest problems affecting the lower half of the gastrointestinal (GI) tract. The most common diagnoses for patients with these symptoms, when chronic in nature, are irritable bowel syndrome (IBS) and chronic constipation, with an estimated pooled community prevalence of 11.2% and 14%, respectively. IBS and chronic constipation represent a substantial burden to patients and society in terms of daily symptoms, quality of life (QoL), work productivity, and health care costs. Indeed, patients experience chronic, disruptive symptoms for many years prior to seeking health care and typically report lengthy and complex treatment histories.
To claim credits for this activity, please visit: www.gihealthfoundation.org/EVAL-PRIMESUPPLEMENT
Abdominal pain, bloating, diarrhea, and constipation are common complaints encountered in primary care clinics, and usually suggest problems affecting the lower half of the gastrointestinal (GI) tract. The most common diagnoses for patients with these symptoms, when chronic in nature, are irritable bowel syndrome (IBS) and chronic constipation, with an estimated pooled community prevalence of 11.2% and 14%, respectively. IBS and chronic constipation represent a substantial burden to patients and society in terms of daily symptoms, quality of life (QoL), work productivity, and health care costs. Indeed, patients experience chronic, disruptive symptoms for many years prior to seeking health care and typically report lengthy and complex treatment histories.
Hemolytic disease of the fetus and newborn (HDFN) is a rare condition with an estimated 3 to 80 cases per 100,000 persons annually in the United States. Nonetheless, the complexity and increased risk for adverse outcomes in such cases requires more targeted approaches to HDFN that minimize or negate the risks associated with intrauterine transfusion. This article focuses on the pathophysiology underlying fetal/newborn allo- and autoimmune diseases, especially HDFN and the current/evolving diagnostic and treatment regimens for HDFN.
This activity is supported by an independent educational grant from Momenta Pha…
Sponsor
This activity is supported by an independent educational grant from Momenta Pha…
Free CME Credit
Hemolytic disease of the fetus and newborn (HDFN) is a rare condition with an estimated 3 to 80 cases per 100,000 persons annually in the United States. Nonetheless, the complexity and increased risk for adverse outcomes in such cases requires more targeted approaches to HDFN that minimize or negate the risks associated with intrauterine transfusion. This article focuses on the pathophysiology underlying fetal/newborn allo- and autoimmune diseases, especially HDFN and the current/evolving diagnostic and treatment regimens for HDFN.
CME CREDITS: .25 CREDITS To receive CME credit, please read the articles and go to www.omniaeducation.com/HDFN to access the post-test and evaluation.
Free CME Credit
Hemolytic disease of the fetus and newborn (HDFN) is a rare condition with an estimated 3 to 80 cases per 100,000 persons annually in the United States. Nonetheless, the complexity and increased risk for adverse outcomes in such cases requires more targeted approaches to HDFN that minimize or negate the risks associated with intrauterine transfusion. This article focuses on the pathophysiology underlying fetal/newborn allo- and autoimmune diseases, especially HDFN and the current/evolving diagnostic and treatment regimens for HDFN.
Vaginal pH modulators (VPMs) add a new class of contraception that is now available in the United States. This method is nonhormonal, woman-controlled, and coitally dependent—and has the potential to increase overall contraceptive use and potentially reduce unintended pregnancy rates.
This CME supplement to OBG Management focuses on VPMs, their attributes, and the methodology surrounding the determination of contraceptive effectiveness.
Vaginal pH modulators (VPMs) add a new class of contraception that is now available in the United States. This method is nonhormonal, woman-controlled, and coitally dependent—and has the potential to increase overall contraceptive use and potentially reduce unintended pregnancy rates.
This CME supplement to OBG Management focuses on VPMs, their attributes, and the methodology surrounding the determination of contraceptive effectiveness.
Vaginal pH modulators (VPMs) add a new class of contraception that is now available in the United States. This method is nonhormonal, woman-controlled, and coitally dependent—and has the potential to increase overall contraceptive use and potentially reduce unintended pregnancy rates.
This CME supplement to OBG Management focuses on VPMs, their attributes, and the methodology surrounding the determination of contraceptive effectiveness.
